focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Does anyone know what time in US will the merger vote result be announced? This could impact our SP on release.
Apologies Bozi. It is very reassuring if he didn't sell any. As with that 1% I estimated that would have accounted for Vulpes purchase which was just over 1% . Thank you for correction. Did you ascertain this from broker ? I want to add but think we are not yet at stage of commercializing PSE test. Can you possibly enquire about when we may see more news on approval ?
Vulpes increased to over 14% on 29th which could account for 1% Director sold few days ago.
OBD has 94% accurate PC test ready to use. UK cannot screen with MRI for PC as there are not enough scanners.
They still needing larger study than current data from UCL. Imagine the time this UK Govt DHSC takes to start saving lives from commonest male cancer.
Primary Bid offer start trading today. This will not cause huge volume.
LTH's know the 4th quarter 2023 should be the start for sales of PC test. Will add if any further drops due to Odey sell off
That 110K was my buy @ 1.429p. Showing as a sell.
It looks like a 600K buy. I can buy smaller amounts at 1.429p Will top up again. News soon.
Yes Cider I am down a lot currently. My average is 4.2p So a few more buys to improve my average.
I still believe this will be proved as the science will show.
I have topped up again at these all time lows. 240157 @ 1.425p
Will add again tomorrow if further falls in price. News is near in my view.
I find the price today disappointing, after so many buys.
There are mostly buys and 2.09 to buy seems a small rise.
Only news will help now.
If we had 100Ksell it would drop fast. But we know how AIM works for PI's
Did anyone watch the presentation ? I was out and would appreciate any opinions. It was a most unfortunate choice of date for update y.day. In a falling fear filled market. I fear that our CEO rarely announces any new collaboration in RNS before the sleuths on here find it. Poor IR for shareholders. Still waiting & waiting for a new collaboration before Sept.
2.08 to buy & 1.98 to sell now on Barc. Had to put limit order at 2.01 for second 200K top up.
Will add again if any drop.
All Buys today. None available since my 200K top up on Barc. If we all just buy a few today can see it going much higher.
Barc now 1.98 for 200K buy & 1.85 for 200K sell.
Soon be back up to 2p in my view.
Price now 1.98 buy & 1.78 sell . Let see if MM can get a few small sells this PM
ML must be close to his average again. We are much further towards optimisation than Feb. Will add on news.
Is any shareholder on here going this morning ?
I may go to see if anyone else attends.
Very interested to see who is present.
PSA blood test is standard for diagnosing PC. It cannot distinguish between an enlarged prostate and PC.
However there is already a UK Co that has a test which can. Oxford Biodynamics. OBD .
Unfortunately their share price is very low currently and I suspect that funding will be required soon.
They have also developed Episwitch test for an individual patients therapeutic response to checkpoint-inhibitor immunotherapy. Which is being used and is a break through in cancer treatment.
Another UK science first. I am not invested currently . But have PC.
This planned NHS test is a CT scan in mobile screening units in a limited number of sites such as car parks.
Huge costs to NHS and tax payers. Another delay to diagnosis if it involves long waiting times and difficulties to access sites.
Our test will be rolled out in US first and then we will see how long any future UK Govt takes to purchase.
First priority of any Govt is to protect its citizens. Sadly not true on any level.
Firstly we cannot hope to develop a POC test with such a tiny placing amount.
Unless it was a JV, or under license.
If the Corepath lab test comes onto the market this year and we can rejoice.
German Medical Diagnostics Co EPIGENOMICS is in talks with an undisclosed US Co
To sell nearly all its assets for $ 11.5 Million
The talks center on EPIGENOMICS blood test to screen for Colon Cancer
The unidentified US Co would also pay Royalties & other costs associated with the commercialisation of a diagnostics product in development.
As soon as Corepath Labs can produce our CIZB test with agreed license fee
THE HIGHER OUR M.Cap will be for any TAKEOVER, or rapid growth.
Will add to my holding in coming week.
Stay Calm Science is Proven.
Dr David Crosby of CRUK Apologies & Correction
"Very early detection is relatively LOW "
The earlier cancer can be detected, the better the outcomes for patients.
CIZ1 can detect early stage Lung Cancer.
Lung Cancer is the World's No 1 cancer.